Verisante Technology, Inc.( (TSX


"Company" or "Verisante"), a leader in cancer detection technology,

announced today that the Company has been named this year's top

ranking Technology and Life Sciences Company on the TSX Venture 50.

The TSX Venture Exchange's annual list of its top 50 emerging publicly

traded companies is a ranking of the strongest performers from five

industry sectors. Verisante ranked number one on the list of top 10

leading Technology and Life Sciences companies for the year. Companies

are selected based on four equally weighted criteria - return on

investment, trading activity, market capitalization growth, and

analyst coverage. The results were obtained from data to December 31,


As the top ranking Technology and Life Sciences Company, Verisante has

been invited to attend the TSX Venture 50 Spotlight event on April 3,

2012 in Toronto, with an opportunity to present to an audience

comprised of portfolio managers, investment bankers, research analysts

and investment advisors.

"The number one ranking by the TSX Venture Exchange underscores the

breakthrough year the Company has had," said Thomas Braun, President

and CEO. "The approval of Verisante Aura for use in the key Canadian,

European and Australian markets and the industry recognition our

technologies have recently received demonstrate that we are moving

forward on our commitment to helping healthcare providers save lives

through the detection of some of the most common forms of cancer."

Verisante Aura has also recently been awarded Popular Science

Magazine's "Best of What's New

Award(" for

2011, and Verisante Core was named one of the top 10 cancer


of 2011 by the Canadian Cancer Society. In addition, the Company was

named a finalist for the 2011 Regional Awards for New


by the Canadian Manufacturers & Exporters and the National Research

Council of Canada.

About Verisante Technology, Inc.

Verisante is a medical device company(

committed to commercializing innovative systems for the early

detection of cancer( The Verisante Aura

for skin cancer detection( and

the Verisante Core series for lung, colon and cervical cancer

detection( utilize a

proprietary cancer detection platform while the operating software and

probe technology are unique to each device. The cancer detection

platform was developed by the BC Cancer Agency and tested and refined

at the Skin Care Centre at Vancouver General Hospital. This exclusive

platform technology allows Verisante to develop and offer a range of

compact, non-invasive cancer detection devices that offer physicians

immediate results( for many of

the most common cancers. The Aura has been approved for sale in

Canada, Europe and Australia. The Core has not yet been approved for





Forward Looking Statements

This release contains forward-looking statements, including, but not

limited to, statements regarding the future commercialization of

medical devices, the market demand for these products and the

proprietary protections the Company will obtain with regard to the

technology, all of which statements are subject to market risks, and

the possibility that the Company will not be able to obtain patent

protection or obtain sufficient customer demand. These statements are

made based upon current expectations and actual results may differ

from those projected due to a number of risks and uncertainties.

The TSX Venture Exchange has neither approved nor disapproved of the

contents of this press release. Neither the TSX Venture Exchange nor

its Regulation Services Provider (as that term is defined in the

policies of the TSX Venture Exchange) accepts responsibility for the

adequacy or accuracy of this press release.